- Research & Development
- About us
- Invest in us
- Malaria & medicines
Interactive R&D portfolio
MMV’s portfolio focuses on delivering efficacious medicines that are affordable, accessible and appropriate for use in malaria endemic areas. Specifically, the goal is to develop products that will provide: efficacy against drug-resistant strains of Plasmodium falciparum, potential for intermittent treatments (infants and pregnancy), safety in small children (less than 6 months old), safety in pregnancy, efficacy against Plasmodium vivax (including radical cure), efficacy against severe malaria, and transmission-blocking treatment.
The MMV project portfolio is updated quarterly. Click on a project below for more information.
- Download MMV's portfolio at end of 4th quarter, 2013 [346Kb]
- Download the global malaria portfolio at end of 4th quarter, 2013. [473Kb]
- Download the global malaria portfolio, classified by therapeutic type at end of 4th quarter, 2013 [627Kb]
For more information about the global malaria portfolio, read the article: The Global Portfolio of New Antimalarial Medicines Under Development.